Annual Conference Schedule
Please join Acella Pharmaceuticals for the following conferences and register to attend one of our product theaters highlighting NP Thyroid®.
June
Endocrine Society
June 11–14 - Atlanta, GA
Attendance: Hybrid (In-person / Online)
Product Theater
Monday, June 13 at 1:00-1:45 pm ET
with Dr. Thanh Hoang, DO, FACP
AANP
June 21–26 - Orlando, FL
Attendance: Hybrid (In-person / Online)
Product Theater
Wednesday, June 22 at 12:00-1:15 pm ET
with Mandy Cotten, APRN, FNP-C
Title
Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients
July
MEDS West
July 13–16 - Newport Beach, CA
Attendance: Hybrid (In-person / Online)
Product Theater
Saturday, July 16 at 7:10-7:55 am PT
with Susan VanBeuge, DNP, FNP-BC, FAANP
Title
Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients
National Nurse Practitioner
Symposium
July 21–24 - Keystone, CO
Attendance: Hybrid (In-person / Online)
Product Theater
Thursday, July 21 at 11:30 am-1:00 pm MT
with Christine Kessler, MN, CNS, ANP, BC-ADM, CDTC, FAANP
Title
Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients
August
Western Endocrine Association
(WEA)
Aug 26-28 - Sedona, AZ
Attendance: Hybrid (In-person / Online)
Booth TBD
September
Hormones & Beyond
September 15–18 - Albuquerque, NM
Attendance: Hybrid (In-person / Online)
Booth TBD
Family Medicine Experience
September 20–24 - Washington, DC
Attendance: Hybrid (In-person / Online)
Product Theater
Thursday, September 22 at 11:30 am-12:15 pm ET
with Robert Quarles, DO
Title
Hypothyroidism Uncovered: A Primary Care Perspective
Texas Nurse Practitioner
Conference
September 22–25 - Round Rock, TX
Attendance: In-person
Product Theater
Thursday, September 22 at 12:15-1:15 pm CT
with Angela Golden, DNP, FNP-C, FAANP
Title
Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients
october
MEDS Fall
October 12–15 - Lake Buena Vista, FL
Attendance: Hybrid (In-person / Online)
Product Theater
Wednesday, October 12 at 8:00-8:45 am ET
with Christine Kessler, MN, CNS, ANP, BC-ADM, CDTC, FAANP
Title
Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients
American Thyroid Association
Conference
October 19–23 - Montreal, Quebec, Canada
Attendance: In-person
Product Theater
October 21 at 11:00 am-12:00 pm ET
with Thanh Hoang, DO, FACP, FACE | David Robertson, MD | Elizabeth McAninch, MD
Title
Treating Hypothyroidism: A Patient Focused Discussion
on the Utility and Perception of Desiccated Thyroid Extract
AMMG
October 27–30 - Denver, CO
Attendance: In-person
Booth TBD
December
A4M
December 9–11 - Las Vegas, NV
Attendance: In-person
Booth TBD
INDICATIONS & IMPORTANT RISK INFORMATION INCLUDING BLACK BOX WARNING
Important Risk Information
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
- NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
- In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
- Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
- The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
- Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
- In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
- Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
- Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
- Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
- NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.
Indication
NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.
NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.